

Report from Chair of Finance and Business Performance (F&BP) Committee

Date of Committee 28 May 2024

Item	Summary of Item	Committee Assured	Further Work Required	Referral Elsewhere for Further Work	Recommendation to Board
Meeting Minutes	Minutes from the meeting on 23 April 2024	Approved	None	Refer to Audit Committee for noting	n/a
Terms of Reference	Annual review of Committee Terms of Reference (ToR)	Approved	None	n/a	To approve
Summary of Operational Improvement & Learning 2023/24	Following the delivery of the 2023/24 objectives, summary of associated improvements and learning to support delivery future objectives	Assured – recognising the need to both greater understand and fill the capabilities deficit within the organisation	None	n/a	n/a
Monthly Integrated Performance Review (IPR)	<p>Monthly reporting on Trust performance metrics and actions/progress with actions to address negative variance (April 2024)</p> <p>First version of a revised IPR to reflect the breakthrough and operational objectives for 2024/25</p>	<p>Assured – welcoming the evolution of the report. The Committee discussed:</p> <ul style="list-style-type: none"> - The need to focus on medium- and long-term objectives, aligned with the Place Strategy. - Key and driver metrics. - Theatre utilisation and cancellation rates. - Opening of new 21-bed ward and associated staffing. - Initiatives to support efficiency in discharge processes. - Development of lead indicators for people metrics. - 65-week breaches. 	None	n/a	To take assurance from the revised report and discussions held by the Committee

Item	Summary of Item	Committee Assured	Further Work Required	Referral Elsewhere for Further Work	Recommendation to Board
Diagnostic Achievements and Milestones	Summary of changes across pathology and radiology during 2023/24 and overview of achievements/ next steps	Assured	None	n/a	n/a
Monthly Finance Report	Update on M01 financial position including performance against year-to-date (YTD) plan and closing cash balance Verbal update on the current position with the 2024/25 financial plan	Assured – recognising the current challenges related to the financial position Noted the upcoming need for additional cash drawdowns and the governance arrangements required thereon.	None	n/a	To take assurance from the report and discussions held by the Committee
National Cost Collection	Overview of the draft mandatory annual cost collection exercise and return to NHS England	Approved – recognising the tight timeframe for submission and the need to use draft accounts for this process accordingly	None	n/a	n/a
Capital Report	Overview of the 2024/25 capital programme and update on capital spend against the annual plan at M01	Assured	None	n/a	n/a
Human Tissue Authority (HTA) Inspection Report	Summary of outcome of an unannounced HTA inspection of SMH mortuary on 22 February 2024 including findings and actions to address	Assured – including discussions regarding the income & expenditure related to mortuary/associated services and confirmation the team were addressing outstanding actions.	Noted that related internal audit outstanding action points would be followed up as a result of this work also.	n/a	To note as part of the paper being provided for information to Board

Item	Summary of Item	Committee Assured	Further Work Required	Referral Elsewhere for Further Work	Recommendation to Board
Commercial Strategy	<p>Overview of delivery of the three-year strategy during 2023/24 and plans for 2024/25</p> <p>NB. Strategy covers the period 2022/23 – 2024/25</p>	Assured – recognising further potential options within the commercial pipeline	<p>Provision of information to allow benchmarking with other similar organisations</p> <p>Detailed options appraisal to be presented to the Committee considering benefits of potential options and resource available</p>	n/a	n/a
NHS Education Funding Agreement	Request to approve three-year agreement for education funding from NHS England	Approved – recognising commissioning arrangements between the Trust and the Health and Social Care Academy	None	n/a	To approve

Emerging Risks noted:

- Cash position.